| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1759720X15591801 |
| P8608 | Fatcat ID | release_vxbbc5ef5rekphve327ylhfovy |
| P932 | PMC publication ID | 4572363 |
| P698 | PubMed publication ID | 26425147 |
| P50 | author | Dafna D. Gladman | Q37605821 |
| P2093 | author name string | Lihi Eder | |
| P2860 | cites work | Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis | Q27007133 |
| Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications | Q28253399 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Macrophages in the pathogenesis of atherosclerosis | Q29617765 | ||
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
| Consensus guidelines for the management of plaque psoriasis. | Q34129100 | ||
| Anti-psoriatic therapy recovers high-density lipoprotein composition and function | Q34259215 | ||
| Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis | Q34348857 | ||
| Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities | Q34434622 | ||
| Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. | Q34478064 | ||
| TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome | Q34571799 | ||
| Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initia | Q34668556 | ||
| Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. | Q35031069 | ||
| Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. | Q35124825 | ||
| Psoriatic arthritis: epidemiology, clinical features, course, and outcome | Q35579437 | ||
| Cardiovascular risk in patients with psoriatic arthritis | Q35974962 | ||
| Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis | Q36030664 | ||
| The impact of psoriasis on 10-year Framingham risk | Q36240763 | ||
| Obesity and the risk of psoriatic arthritis: a population-based study. | Q36820863 | ||
| Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis | Q36957991 | ||
| Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? | Q37026106 | ||
| Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points | Q37235254 | ||
| Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? | Q37279687 | ||
| Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study | Q37449514 | ||
| The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37640953 | ||
| Atherosclerosis: current pathogenesis and therapeutic options | Q37953777 | ||
| Ultrasound and radiology surrogate endpoints in pharmacological studies | Q38013330 | ||
| The association between psoriasis and dyslipidaemia: a systematic review | Q38056160 | ||
| Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis. | Q38118351 | ||
| From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies | Q38159088 | ||
| Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? | Q38185646 | ||
| Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations | Q38264287 | ||
| Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity | Q41453068 | ||
| Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. | Q42613896 | ||
| Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity | Q43472253 | ||
| Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study | Q43578147 | ||
| Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis | Q44270837 | ||
| Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. | Q44289756 | ||
| The prevalence of psoriatic arthritis in people with psoriasis | Q44297644 | ||
| Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis | Q44368185 | ||
| Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
| Subclinical carotid atherosclerosis in patients with psoriatic arthritis | Q46401856 | ||
| Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both | Q46624658 | ||
| Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease | Q46822082 | ||
| Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. | Q50552445 | ||
| Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. | Q50562732 | ||
| Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. | Q50701991 | ||
| Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. | Q51009674 | ||
| Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. | Q53249650 | ||
| Psoriasis | Q56115292 | ||
| Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study | Q57232023 | ||
| Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors | Q57307113 | ||
| Pulling down the plug on atherosclerosis: Cooling down the inflammasome | Q57348696 | ||
| Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study | Q59123662 | ||
| Cardiovascular morbidity in psoriatic arthritis | Q60699917 | ||
| Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque | Q69990504 | ||
| Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis | Q79305514 | ||
| Differences in body mass index among individuals with PsA, psoriasis, RA and the general population | Q82696202 | ||
| The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity | Q83630245 | ||
| Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors | Q86753213 | ||
| The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease | Q87149575 | ||
| Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery | Q87606546 | ||
| Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis | Q87874278 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 187-95 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Therapeutic advances in musculoskeletal disease | Q26841913 |
| P1476 | title | Atherosclerosis in psoriatic disease: latest evidence and clinical implications | |
| P478 | volume | 7 |
| Q49276761 | Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness |
| Q33744214 | C-X-C motif chemokine ligand 8 promotes endothelial cell homing via the Akt-signal transducer and activator of transcription pathway to accelerate healing of ischemic and hypoxic skin ulcers |
| Q40069191 | Cardiometabolic Disorders in Psoriatic Disease |
| Q92148213 | Cardiovascular Risk in Psoriasis Patients: Clinical, Functional and Morphological Parameters |
| Q90564046 | Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report |
| Q98613169 | Changes in metabolic parameters in psoriatic patients treated with secukinumab |
| Q51244473 | Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease. |
| Q63560422 | Inflammasome Signaling and Impaired Vascular Health in Psoriasis |
| Q39428387 | Linking Brain Arteriovenous Malformations With Anorectal Hemorrhoids: A Clinical and Anatomical Review |
| Q48239956 | Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab). |
| Q91878137 | Obesity in psoriatic arthritis: Comparative prevalence and associated factors |
| Q58785751 | Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows |
| Q88812010 | Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment |
| Q55512008 | T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. |
| Q47884794 | Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by (18)Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study |
Search more.